Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
Clinical trial NCT07634094 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07634094
- Sponsor
- Kalinski, Pawel, MD, PhD
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2028-08-01
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.